Cargando…
A pilot exploration with Posiphen to normalize amyloid precursor protein in Down syndrome
Autor principal: | Chen, Xu-Qiao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374580/ https://www.ncbi.nlm.nih.gov/pubmed/33907026 http://dx.doi.org/10.4103/1673-5374.313044 |
Ejemplares similares
-
Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans
por: Maccecchini, Maria L, et al.
Publicado: (2012) -
Posiphen Reduces the Levels of Huntingtin Protein through Translation Suppression
por: Chen, Xu-Qiao, et al.
Publicado: (2021) -
Amyloid Precursor Protein (APP) and GABAergic Neurotransmission
por: Tang, Bor Luen
Publicado: (2019) -
Targeting amyloid precursor protein shuttling and processing - long before amyloid beta formation
por: Arbor, Sage
Publicado: (2017) -
Targeting increased levels of APP in Down syndrome: Posiphen‐mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model
por: Chen, Xu‐Qiao, et al.
Publicado: (2020)